Holen Sie sich die Stockscreener-App
24.13
0.50%
0.12
Handel nachbörslich:
24.13
Schlusskurs vom Vortag:
$24.01
Offen:
$23.86
24-Stunden-Volumen:
3.70M
Relative Volume:
6.43
Marktkapitalisierung:
$1.69B
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-11.28
EPS:
-2.14
Netto-Cashflow:
$23.50M
1W Leistung:
+0.42%
1M Leistung:
+1.73%
6M Leistung:
+24.57%
1J Leistung:
+18.40%
1-Tages-Spanne:
$23.52
$25.02
1-Wochen-Bereich:
$22.74
$25.54
52-Wochen-Spanne:
$15.31
$27.24
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Vergleichen Sie XNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
24.13 | 1.69B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics - The Globe and Mail
Fmr LLC Buys 12,729 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Jane Street Group LLC Has $3.39 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
State Street Corp Reduces Stake in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
When (XNCR) Moves Investors should Listen - Stock Traders Daily
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Xencor (NASDAQ:XNCR) Earns Overweight Rating from Analysts at Wells Fargo & Company - Defense World
Xencor's SWOT analysis: biotech stock balances promise and challenges - Investing.com
Xencor's SWOT analysis: biotech stock balances promise and challenges By Investing.com - Investing.com South Africa
Wells Fargo Initiates Coverage of Xencor (XNCR) with Overweight Recommendation - MSN
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy - MSN
Xencor (NASDAQ:XNCR) Now Covered by Wells Fargo & Company - MarketBeat
The Manufacturers Life Insurance Company Reduces Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Charles Schwab Investment Management Inc. Has $12.61 Million Holdings in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
(XNCR) Technical Pivots with Risk Controls - Stock Traders Daily
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
46,700 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Polar Asset Management Partners Inc. - MarketBeat
Readystate Asset Management LP Buys New Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet - MSN
RTW Investments LP Takes $11.56 Million Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
RA Capital Management L.P. Makes New Investment in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Point72 Asset Management L.P. Purchases 1,858,440 Shares of Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Xencor director Montgomery sells $397,930 in stock - Investing.com India
Xencor director Montgomery sells $397,930 in stock By Investing.com - Investing.com Canada
Fed. Circ. Judge Condemns 'Nonsense' Law In Antibody Fight - Law360
Piper Sandler Upgrades Xencor (XNCR) - MSN
Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up - Simply Wall St
Xencor stock hits 52-week high at $26.89 amid robust gains - Investing.com Canada
Piper Sandler upgrades Xencor stock, highlights expanding pipeline and Phase I/II data - Investing.com Nigeria
Xencor stock hits 52-week high at $26.89 amid robust gains By Investing.com - Investing.com South Africa
Baker BROS. Advisors LP Purchases 125,000 Shares of Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Critical Insights From Xencor Analyst Ratings: What You Need To Know - Inkl
Erste Asset Management GmbH Takes Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $362,000 in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Victory Capital Management Inc. Trims Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Braidwell LP Makes New Investment in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Short Interest in Xencor, Inc. (NASDAQ:XNCR) Declines By 18.2% - MarketBeat
Thrivent Financial for Lutherans Raises Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Thrivent Financial for Lutherans Acquires 65,180 Shares of Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Loomis Sayles & Co. L P Has $18.10 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Objective long/short (XNCR) Report - Stock Traders Daily
Xencor to Participate at Upcoming Investor Conferences - sharewise
Xencor to Present at Two Major Healthcare Investor Conferences in December | XNCR Stock News - StockTitan
Xencor CEO Bassil Dahiyat sells $1.19 million in stock By Investing.com - Investing.com Nigeria
Xencor CEO Bassil Dahiyat sells $1.19 million in stock - Investing.com India
KBC Group NV Acquires 1,213 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xencor Inc-Aktie (XNCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Montgomery Alan Bruce | Director |
Dec 04 '24 |
Option Exercise |
16.76 |
1,421 |
23,812 |
10,561 |
| Montgomery Alan Bruce | Director |
Dec 02 '24 |
Sale |
27.03 |
13,301 |
359,525 |
9,140 |
| Montgomery Alan Bruce | Director |
Dec 04 '24 |
Sale |
27.03 |
1,421 |
38,406 |
9,140 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):